Literature DB >> 7528014

Cytochrome P4502A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes.

P Salonpää1, O Pelkonen, A Kojo, M Pasanen, M Negishi, H Raunio.   

Abstract

Factors involved in CYP2A5 expression were studied in mouse liver primary hepatocytes in culture. CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). The constitutive activity and inducibility of COH was totally blocked by treatment of hepatocytes with actinomycin D, and short initial treatment with cycloheximide caused superinducibility when co-administered with PB. Treatment of hepatocytes with inhibitors of protein kinase C, tyrosine kinases and a generator of nitric oxide did not affect COH basal activity or inducibility. Administration of dibutyryl cAMP, forskolin, and 3-isobutyl-1-methylxanthine (IBMX) enhanced both basal and PB-induced COH activities and CYP2A5 mRNA levels, indicating that cAMP plays a major role in CYP2A5 expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528014     DOI: 10.1006/bbrc.1994.2712

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Alcoholic Liver Disease: from CYP2E1 to CYP2A5.

Authors:  Tung Ming Leung; Yongke Lu
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  Protein serine/threonine phosphatase inhibitors suppress phenobarbital-induced Cyp2b10 gene transcription in mouse primary hepatocytes.

Authors:  P Honkakoski; M Negishi
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  Farnesoid X receptor represses hepatic human APOA gene expression.

Authors:  Indumathi Chennamsetty; Thierry Claudel; Karam M Kostner; Anna Baghdasaryan; Dagmar Kratky; Sanja Levak-Frank; Sasa Frank; Frank J Gonzalez; Michael Trauner; Gert M Kostner
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Authors:  Indumathi Chennamsetty; Karam M Kostner; Thierry Claudel; Manjula Vinod; Sasa Frank; Thomas S Weiss; Michael Trauner; Gerhard M Kostner
Journal:  J Lipid Res       Date:  2012-08-28       Impact factor: 5.922

5.  Genetic analysis of the phenobarbital regulation of the cytochrome P-450 2b-9 and aldehyde dehydrogenase type 2 mRNAs in mouse liver.

Authors:  M Damon; A Fautrel; A Guillouzo; L Corcos
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

6.  Pyrazole-inducible proteins in DBA/2 mouse liver bind with high affinity to the 3'-untranslated regions of the mRNAs of coumarin hydroxylase (CYP2A5) and c-jun.

Authors:  M Thulke-Gross; M Hergenhahn; A Tilloy-Ellul; M Lang; H Bartsch
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

7.  Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver.

Authors:  P Salonpää; K Krause; O Pelkonen; H Raunio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

8.  Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I.

Authors:  Johanna Ulvila; Satu Arpiainen; Olavi Pelkonen; Kaoru Aida; Tatsuya Sueyoshi; Masahiko Negishi; Jukka Hakkola
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

Review 9.  Cytochrome P450s and Alcoholic Liver Disease.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

10.  Identification and characterization of a FOXA2-regulated transcriptional enhancer at a type 2 diabetes intronic locus that controls GCKR expression in liver cells.

Authors:  Maykel López Rodríguez; Dorota Kaminska; Kati Lappalainen; Jussi Pihlajamäki; Minna U Kaikkonen; Markku Laakso
Journal:  Genome Med       Date:  2017-07-06       Impact factor: 11.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.